Michael J. Fox Foundation and Parkinson’s UK Award $5.2 Million to Mission Therapeutics for Research into Potential Parkinson’s Treatment

July 5, 2024 - By admin

MTX325 is in Phase I trials and is believed to be able to modify the course of the disease.